Skip to content Skip to footer
Viewpoints_Jesse Mendelsohn

Predicting 2025 Trends: Jesse Mendelsohn from Model N in an Illuminating Discussion with PharmaShots

Shots:  Several undulating factors coalesce to inadvertently shape the biopharma industry  Prominent challenges include mounting pressure on Pharmacy Benefit Managers from independent pharmacies and drug manufacturers, a growing shortage of GLP-1 drugs, and the addition of 15 more drugs to the Inflation Reduction Act’s price negotiation list.  Jesse Mendelsohn, SVP at Model N, emphasizes the…

Read more

VIEWPOINTS_Kyle Forcier_2023

In a gripping conversation with PharmaShots, Kyle Forcier addresses the ways to avoid the challenges of the 340B program

Shots:  Kyle Forcier, Sr. Director of Life Science Product Marketing at Model N, addresses the challenges of the 340B program and ways manufacturers can mitigate them and emerge stronger   340B, a US federal government plan, enables eligible healthcare organizations and covered entities to receive outpatient drugs from drug manufacturers at significantly low prices   Kyle recalls…

Read more